Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations

Histopathology

Volumn 50, Issue 4, 2007, Pages 448-452

  Liegl, B ^a   Gully C ^a   Reich, O ^a   Nogales, F F ^b   Beham, A ^a   Regauer, S ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

Autocrine stimulation; C kit; Gleevec; Stromal tumours; Treatment

Indexed keywords

AMINO ACID; IMATINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM SARCOMA; EXON; FEMALE; FREEZING; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; METASTASIS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; TUMOR CELL;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; SARCOMA, ENDOMETRIAL STROMAL;

EID: 33847320613     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02634.x     Document Type: Article

References (28)

1. Reich O, Regauer S, Urdl W et al. Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br. J. Cancer 2000; 82; 1030-1034.
2. Reich O, Regauer S, Urdl W. Heterogeneous oestrogen- and progesterone-receptor expression in low-grade endometrial stromal sarcomas - implications for therapy. Eur J. Cancer 2000; 36 (Suppl. 4); 108.
3. Reich O, Regauer S. Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod. Pathol. 2004; 17; 104-108.
4. Reich O, Regauer S. Endometrial stromal sarcoma - observational evidence of a genetic background? Eur. J. Gynecol. Oncol. 2005; 26; 288-290.
5. Reich O, Nogales FF, Regauer S. Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study. Mod. Pathol. 2005; 18; 573-576.
6. Gadducci A, Sartori E, Landoni F et al. Endometrial stroma sarcoma: analysis of treatment failures and survival. Gynecol. Oncol. 1996; 63; 247-253.
7. Klaritsch P, Reich O, Bauernhofer T et al. Recurrent endometrial stromal sarcoma after treatment with high-dose chemotherapy and autologous stem cell support - a case report. Eur. J. Gynaecol. Oncol. 2006; 27; 297-298.
8. Chang KL, Crabtree GS, Lee-Tan SK et al. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am. J. Surg. Pathol. 1990; 14; 415-438.
9. Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv. Anat. Pathol. 2000; 7; 257-281.
10. Moinfar F, Gogg-Kamerer M, Sommersacher A et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am. J. Surg. Pathol. 2005; 29; 485-489.
11. El-Rifai W, Sarlomo-Rikala M, Andersson LC et al. DNA copy number changes in gastrointestinal stromal tumors - a distinct genetic entity. Ann. Chir. Gynaecol. 1998; 87; 287-290.
12. Heinrich MC, Rubin BP, Longley BJ et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol.2002; 33; 484-495.
13. Hirota S, Ohashi A, Nishida T. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003; 125; 660-667.
14. Heinrich MC, Corless CL, Duensing A. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299; 708-710.
15. Klein WM, Kurman RJ. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int. J. Gynecol. Pathol. 2003; 22; 181-184.
16. Liegl B, Reich O, Nogales FF et al. PDGFα and PDGFβ are expressed in endometrial stromal sarcoma: a potential therapeutic target for tyrosine kinase inhibitors? Histopathology 2006; 49; 545-546.
17. Wilczynski SP, Chen YY, Chen W et al. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers. Hum. Pathol. 2005; 36; 242-249.
18. Sihto H, Sarlomo-Rikala M, Tynninen O et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J. Clin. Oncol. 2005; 23; 49-57.
19. Kindler T, Breitenbuecher F, Marx A et al. Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood 2004; 103; 3644-3654.
20. Lassus H, Sihto H, Leminen A et al. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma. Br. J. Cancer 2004; 91; 2048-2055.
21. Lindahl P, Johansson BR, Leveen P et al. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997; 277; 242-245.
22. Lindblom P, Gerhardt H, Liebner S et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 2003; 17; 1835-1840.
23. Reuterdahl C, Sundberg C, Rubin K et al. Tissue localization of beta receptors for platelet-derived growth factor and platelet-derived growth factor B chain during wound repair in humans. J. Clin. Invest. 1993; 91; 2065-2075.
24. Battegay EJ, Rupp J, Iruela-Arispe L et al. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J. Cell Biol. 1994; 125; 917-928.
25. Sano H, Ueda Y, Takakura N et al. Blockade of platelet-derived growth factor receptor-beta pathway induces apoptosis of vascular endothelial cells and disrupts glomerular capillary formation in neonatal mice. Am. J. Pathol. 2002; 161; 135-143.
26. Apte SM, Bucana CD, Killion JJ et al. Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines. Gynecol. Oncol. 2004; 93; 78-86.
27. Pietras K, Rubin K, Sjoblom T et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002; 62; 5476-5484.
28. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin. Oncol. 2004; 31; 18-23.